• Explore /
  • Poster
  • / CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).

CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

null

Guillermo de Velasco

Department of Medical Oncology, University Hospital 12 de Octubre, i + 12, Madrid, Spain., Madrid, Spain

Guillermo de Velasco , Borja González , Teresa Alonso , Alvaro Pinto , Juan Francisco Rodriguez-Moreno , Juan Manuel Sepúlveda , Jose Carlos Villa , Natalia Miranda , Félix Guerrero , Daniel E. Castellano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4603)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4603

Abstract #

TPS4603

Poster Bd #

420b

Abstract Disclosures

Similar Posters

First Author: Giuseppe Procopio

Poster

2022 ASCO Genitourinary Cancers Symposium

Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.

Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.

First Author: Mehmet Asim Bilen

First Author: Elena Verzoni

First Author: Albert Font Pous